Jefferies Financial Group Boosts AstraZeneca (LON:AZN) Price Target to GBX 74

AstraZeneca (LON:AZN) had its target price upped by Jefferies Financial Group from GBX 71 ($0.90) to GBX 74 ($0.94) in a report issued on Tuesday morning, Marketbeat Ratings reports. They currently have a hold rating on the biopharmaceutical company’s stock.

Several other equities analysts have also issued reports on the stock. Berenberg Bank lifted their price objective on shares of AstraZeneca from £130 ($164.43) to £150 ($189.73) and gave the company a buy rating in a report on Friday, June 7th. JPMorgan Chase & Co. reissued an overweight rating on shares of AstraZeneca in a report on Tuesday, June 4th. Citigroup reissued a buy rating on shares of AstraZeneca in a report on Tuesday, May 28th. Barclays reissued an overweight rating and set a £125 ($158.11) price objective on shares of AstraZeneca in a report on Monday, April 8th. Finally, Deutsche Bank Aktiengesellschaft reissued a hold rating and set a £110 ($139.13) price objective on shares of AstraZeneca in a report on Tuesday, June 18th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of £105.53 ($133.49).

AstraZeneca Stock Performance

AstraZeneca stock opened at £121.06 ($153.12) on Tuesday. The company has a 50 day moving average price of £122.82 and a 200-day moving average price of £111.13. The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. AstraZeneca has a fifty-two week low of GBX 9,461 ($119.67) and a fifty-two week high of £127.04 ($160.69). The company has a market capitalization of £187.64 billion, a PE ratio of 3,885.60, a P/E/G ratio of 0.97 and a beta of 0.16.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.